Get started
Author

Maria-Elisabeth Goebeler

Observed names: Goebeler, Maria-Elisabeth, Maria‐Elisabeth Goebeler
Observed institutions: Universität Ulm, Johannes Gutenberg University Mainz, Heidelberg University, University of Würzburg, University Hospital Heidelberg, Centre Hospitalier Universitaire de Tours, Comprehensive Cancer Center Mainfranken, Universitätsklinikum Würzburg
ORCID: 0000-0001-5150-3378
Observed ORCID: 0000-0001-5150-3378
OpenAlex ID: A5108937915
T cell-engaging therapies — BiTEs and beyond
2020 · Maria-Elisabeth Goebeler, Ralf C. Bargou · Nature Reviews Clinical Oncology · 649
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
2016 · Maria-Elisabeth Goebeler, Stefan Knop, et al. · Journal of Clinical Oncology · 428
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma
2021 · Matteo C. Da Vià, Oliver Dietrich, et al. · Nature Medicine · 327
Bispecific and multispecific antibodies in oncology: opportunities and challenges
2024 · Maria-Elisabeth Goebeler, Gernot Stuhler, et al. · Nature Reviews Clinical Oncology · 182
Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy
2016 · Maria-Elisabeth Goebeler, Ralf Bargou · Leukemia & lymphoma/Leukemia and lymphoma · 170
Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML
2021 · Martin Wermke, Sabrina Kraus, et al. · Blood · 167
PDF
Pasotuxizumab, a Bite ® Immune Therapy for Castration-Resistant Prostate Cancer: Phase I, Dose-Escalation Study Findings
2020 · Horst-Dieter Hummel, Peter Kufer, et al. · Immunotherapy · 153
PDF
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours
2024 · Ignacio Melero, Maria de Miguel Luken, et al. · Nature · 132
PDF
Poor efficacy and tolerability of R‐CHOP in relapsed/refractory chronic lymphocytic leukemia and R ichter transformation
2014 · Petra Langerbeins, Raymonde Busch, et al. · American Journal of Hematology · 114
PDF
Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab
2019 · Vera Dufner, Cyrus M. Sayehli, et al. · Blood Advances · 91
DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function
2022 · Ildiko Madurka, Alexander Vishnevsky, et al. · Infection · 90
PDF
Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events
2019 · Matthias Klinger, Gerhard Zugmaier, et al. · Cancer Research · 85
Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML
2015 · for the SAKK and the German CML Study Group, Alice Fabarius, et al. · Annals of Hematology · 81
Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC).
2019 · Horst-Dieter Hummel, Peter Kufer, et al. · Journal of Clinical Oncology · 58
Phase I study of domatinostat (4 SC ‐202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies
2018 · Bastian von Tresckow, Cyrus Sayehli, et al. · European Journal Of Haematology · 50
Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors
2023 · Todd M Bauer, Armando Santoro, et al. · Journal for ImmunoTherapy of Cancer · 46
PDF
Updated Results from a Phase I Dose Escalation Study of the Rapidly-Switchable Universal CAR-T Therapy UniCAR-T-CD123 in Relapsed/Refractory AML
2023 · Martin Wermke, Stephan Metzelder, et al. · Blood · 41
Phase 1 Dose Escalation Study of the Rapidly Switchable Universal CAR-T Therapy Unicar-T-CD123 in Relapsed/Refractory AML
2022 · Gerhard Ehninger, Sabrina Kraus, et al. · Blood · 40
Volumetric absorptive microsampling (VAMS) for the quantification of ten kinase inhibitors and determination of their in vitro VAMS-to-plasma ratio
2022 · Sebastian Zimmermann, Fatemeh Aghai, et al. · Journal of Pharmaceutical and Biomedical Analysis · 33
Phase Ib study of the anti-TGF-β monoclonal antibody (mAb) NIS793 combined with spartalizumab (PDR001), a PD-1 inhibitor, in patients (pts) with advanced solid tumors.
2021 · Todd Michael Bauer, Chia-Chi Lin, et al. · Journal of Clinical Oncology · 29
Phase I study of pasotuxizumab (AMG 212/BAY 2010112), a PSMA-targeting BiTE (Bispecific T-cell Engager) immune therapy for metastatic castration-resistant prostate cancer (mCRPC).
2020 · Horst-Dieter Hummel, Peter Kufer, et al. · Journal of Clinical Oncology · 25
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
2018 · Christian Michel, Andreas Burchert, et al. · Haematologica · 22
PDF
Identification of Disparities in Personalized Cancer Care—A Joint Approach of the German WERA Consortium
2022 · Florian Lüke, Florian Haller, et al. · Cancers · 21
PDF
Abstract PR006: Initial results from first-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in biomarker-selected solid tumors
2023 · Jordi Rodon, Noboru Yamamoto, et al. · Molecular Cancer Therapeutics · 17
The identification of patient‐specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild‐type melanomas
2018 · Silke Appenzeller, Anja Gesierich, et al. · Cancer · 17
PDF
Works count: 58
Citation count: 3,219
H-index: 22
I10-index: 30
Year
Topic
Type